MODULE 1

Antihyperglycemics and Atherosclerotic Vascular Disease (ASCVD):
What Cardiologists Need to Know





Self-Assessment Program

Step 1: Watch the video

Step 2: Test your knowledge

Step 3: Complete the evaluation form

Step 4: Receive your certificate





X FACULTY

Chair:

Subodh Verma
MD, PhD, FRCSC, FAHA

Professor of Surgery and Pharmacology and Toxicology,
University of Toronto
Canadian Research Chair in Cardiovascular Surgery
Toronto, ON, Canada



 

G. B. John Mancini
MD, FRCP(C), FACP, FACC

Professor of Medicine, University of British Columbia
Director, Research, UBC Division of Cardiology
Director, Cardiovascular Imaging Research Core Laboratory (CIRCL)
Director, CardioRisk Clinic, Vancouver Hospital
Staff Cardiologist, Healthy Heart Program Prevention Clinic, St Paul’s Hospital
Vancouver, BC, Canada



 

Sue Pedersen
MD, FRCPC, ABOM

Specialist in Endocrinology & Metabolism
Diplomate, American Board of Obesity Medicine
C-ENDO Diabetes & Endocrinology Clinic
Calgary, AB, Canada
COMPLETE BIO (ajouter bouton complete bio)



X COMPLETE BIO

Subodh Verma

MD, PhD, FRCSC, FAHA

Cardiac Surgeon, St. Michael’s Hospital, Unity Health Toronto
Scientist, Keenan Research Centre for Biomedical Science and Li Ka Shing
Knowledge Institute of Unity Health Toronto
Professor of Surgery and Pharmacology & Toxicology, University of Toronto
Canada Research Chair in Cardiovascular Surgery
Toronto, ON, Canada


Dr. Subodh Verma is an internationally renowned cardiac surgeon scientist and Professor at the University of Toronto. He is the current Canada Research Chair in Cardiovascular Surgery, having previously served as the Canada Research Chair in Atherosclerosis (2007-2017). Dr. Verma is a past recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He is an appointee of the American Association of Thoracic Surgeons (AATS) and a member of the College of New Scholars, Artists and Scientists, Royal Society of Canada. According to Google Scholar in April 2021, Dr. Verma has an h-index of 100 and his work has been cited over 50,000 times.

Dr. Verma has published extensively in highly impactful journals like the NEJM, Lancet, Circulation, JACC, Nature, and JCI. He is an Associate Editor of the European Heart Journal. Dr. Verma is an active contributor to Canadian clinical practice guidelines and co-authored the recently updated recommendations for atrial fibrillation, antiplatelet therapy, diabetes, and heart failure; he was a member of the 2018 AATS consensus guidelines committee on bicuspid aortic valve-related aortopathy. Dr. Verma has served in various capacities on the American Heart Association Council on Cardiovascular Surgery and Anesthesia since 2008.

Dr. Verma had/has leadership roles on 10 contemporary global heart failure trials – several of which have let to paradigm changes in how individuals all around the world who live with diabetes and heart failure are now managed. He founded and oversees the CardioLink platform at St Michael’s Hospital that is conducting cardiometabolic and surgically oriented RCTs and translational studies. Dr. Verma leads a dynamic pre-clinical and translational research team that leverages preclinical disease models and clinical trial-derived data to identify novel mediators of cardiovascular and cardiometabolic disease as well as answer timely and relevant healthcare questions. His research has yielded 2 United States patents and is supported by several national peer-reviewed grants.

X COMPLETE BIO

G. B. John Mancini

MD, FRCP(C), FACP, FACC

Professor of Medicine, University of British Columbia
Director, Research, UBC Division of Cardiology
Director, Cardiovascular Imaging Research Core Laboratory (CIRCL)
Director, CardioRisk Clinic, Vancouver Hospital
Staff Cardiologist, Healthy Heart Program Prevention Clinic, St Paul’s Hospital
Vancouver, BC, Canada

Dr. Mancini received his MD degree from the University of Toronto (1977), did his residency at St. Michael’s and Toronto General Hospitals and was a Cardiology and Research Fellow at the University of California at San Diego. After a year in the rank of Clinical Assistant Professor at U.C. San Diego, he joined the faculty of the University of Michigan in 1983 where he achieved the rank of tenured Professor and became the Chief of the V.A. Section of Cardiology and Associate Chief of the University of Michigan, Division of Cardiology. He then became Chair of Medicine at the University of British Columbia, 1992-2002.

Dr. Mancini remains a tenured Professor of Medicine at the University of British Columbia and directs an imaging-based research program (Cardiovascular Imaging Research Core Laboratory, CIRCL) that includes facilities for quantitative coronary angiography, ultrasound analyses (coronaries, carotids and brachial artery for atherosclerosis and endothelial function assessments) and cardiac computed tomography. This program has been actively funded for over 30 years, originating at the University of Michigan and transferred to UBC in 1992. Dr. Mancini’s interest focuses on the integration of multi-modality cardiac imaging in multicenter clinical trials for assessment of structural and functional aspects of coronary atherosclerosis and for primary and secondary cardiovascular risk reduction. He has published over three hundred journal articles, abstracts, books, and book chapters.

He is a Fellow of the American College of Cardiology, prior Governor of the American College of Cardiology (British Columbia), a member of the Circulation Council of the American Heart Association, Past President of the Canadian Society for Clinical Investigation, past Editorial Board Member of the Journal of the American College of Cardiology and the American Journal of Cardiology and a member of numerous professional associations in the United States and Canada. He serves as a reviewer for many journals and is currently a member of the editorial boards of the Canadian Journal of Cardiology, and the International Journal of Cardiac Imaging. He is also an Associate Editor of Atherosclerosis.

As Research Director of the UBC Division of Cardiology, Dr. Mancini has developed processes intended to help mentor new faculty by providing competitive funding for pilot projects intended to help start thematic research careers. Through development of research infrastructure support, the role helps facilitate development of competitive grant submissions to external agencies. Success in this arena is fully integrated with the recently established Centre of Cardiovascular Innovation at UBC which serves as an umbrella organization for excellence in all aspects of cardiovascular research from within the Division but also provincially, nationally, and internationally.

Dr. Mancini remains in active practice in the Vancouver Hospital Cardiology Outpatient Clinic, where he directs the CardioRisk Clinic. He also works in the St. Paul's Hospital Healthy Heart Program/Prevention Clinic. A major clinical focus of the CardioRisk Clinic is to foster innovation in novel CV risk detection and therapy, to support FH Canada for the identification and treatment of patients with Familial Hypercholesterolemia and to support the SAVE BC program to identify patients and families with very early atherosclerotic heart disease to understand the causes and identify novel risk factors. Provision of comprehensive primary and secondary CV preventive therapies also serves to create a unique environment for clinical training of residents and fellows in parallel with clinical research opportunities.

X COMPLETE BIO

Sue Pedersen

MD, FRCPC, ABOM

Specialist in Endocrinology & Metabolism
Diplomate, American Board of Obesity Medicine
C-ENDO Diabetes & Endocrinology Clinic
Calgary, AB, Canada

Dr. Sue Pedersen is a Specialist in Endocrinology & Metabolism and a Diplomate of the American Board of Obesity Medicine. She has a busy practice at the C-ENDO Diabetes and Endocrinology Clinic in Calgary. Dr. Pedersen is involved extensively in clinical research for diabetes and obesity. She is a member of the Expert Committee for the 2018 Diabetes Canada Guidelines, and the lead author of the pharmacotherapy chapter on the 2020 Canadian Obesity Guidelines. Dr. Pedersen has become a leading voice on how to treat diabetes and obesity and educates health care professionals globally. She has a public information website about weight management and diabetes: www.drsue.ca

.
X LEARNING OBJECTIVES

After completing this module, clinicians and other healthcare professionals will be better able to:

  • Describe the relationship between diabetes and ASCVD
  • Integrate current guideline recommendations and clinical trial evidence with SGLT2 inhibitors and GLP-IRA to:
    • Optimize CV protection in people with diabetes at high-risk for ASCVD, and
    • Improve CV outcomes in patients with diabetes and established ASCVD
X ACCREDITATION

This event is an Accredited Self-Assessment Program under Section 3 as defined by the Royal College of Physicians & Surgeons of Canada for the Maintenance of Certification program and has been approved by the Canadian Cardiovascular Society. This program was co-developed with the Canadian Cardiovascular Society and was planned to achieve scientific integrity, objectivity, and balance. You may claim a maximum of 2 hours (credits are automatically calculated).

X DISCLOSURES

This program was made possible through an educational grant from AstraZeneca, Bayer Canada, Boehringer Ingelheim, Lilly Canada, Janssen, HLS Therapeutics Inc., Novartis & Novo Nordisk.